2021/1/24  
英文 English 
Medigen says vaccine candidate similar to Moderna’s  (2020/11/24)

U.S. biotech firm Moderna has said its experimental vaccine is 95% effective in preventing COVID-19. On Tuesday, a Taiwan company told reporters that its own vaccine candidate is similar to the one by Moderna.

Charles Chen
Medigen Vaccine Biologics
We and Moderna have ended up producing vaccines with the same antigens. Moderna’s vaccine candidate requires cold storage, though not extremely cold storage. In contrast, Medigen’s vaccine candidate is stable when stored between 2 and 8 degrees Celsius. We’ve already enrolled all the subjects for our Phase I trial. That has gone very smoothly. We expect that at the end of this month or early December, we’ll have sent in the final documentation for our Phase II application. I’m confident that we can start Phase II in late December.


Medigen’s vaccine is currently in Phase I trials. It hopes to wrap up Phase II by next May, and to start production on its first batch of 1 million doses. Medigen is one of three Taiwanese companies that are working on a COVID vaccine. Currently all three of their candidates are in Phase I trials.
中文 Chinese  
捷報! 高端與莫納德採同技術 兩者抗體相近

全球加緊研發武肺疫苗,目前台灣國光、聯亞、高端三家公司 都在一期人體試驗階段,其中高端疫苗的技術和抗體,都跟美國莫德納相近。高端疫苗也宣布力拼明年五、六月完成二期臨床實驗。

[[高端疫苗總經理 陳燦堅]]
“我們兩家疫苗廠,生產出來的抗原最後是一致的。(莫德納)它基本上是需要低溫,但是不需要超低溫,但是相對的高端疫苗,在它的穩定性上面,是可以在一般的2到8度來保存。我們一期已經收案完成,非常順利,我們預期在這個月底12月初,會送二期的臨床的,一個叫審查的最後一個文件,那麼相信會預期在12月下旬,順利開展我們二期臨床試驗。”

高端預期,順利的話,最快明年五月底產出第一批疫苗,準備好一百萬劑,提供國人使用。
關於民視 常見問題 如何收看民視 意見信箱

© 2009 FTV All Rights Reserved 版權所有‧盜用必究 Designed by FTV
地址:244 新北市林口區信義路99號   觀服電話:(02)8601-8601 服務時間:週一至週日09:00-21:00   傳真:(02)8601-3955

本網站使用 cookie 與其他技術為您提供更好的使用體驗, 請閱讀我們的的隱私權政策,通過使用我們的網站,表示您確認並同意我們的政策。